Foresite closes $100M growth capital fund for late-stage healthcare companies
Foresite Capital Management, a growth equity firm founded by Jim Tananbaum to finance late-stage healthcare companies, has closed its $100 million fund, Foresite Capital Fund I. The firm draws on Tananbaum and his partners' experience and expertise in building leading healthcare companies, as well as their broad private and public investment experience.
"We are marrying the best practices of growth investing with healthcare specialization," said Tananbaum, founder and managing director of Foresite Capital Management. "We are proud of our capital base, extremely excited about the prospects for healthcare growth, and believe on a risk-adjusted basis there has never been a better time to have this focus."
Foresite Capital invests in companies with disruptive, late-stage products and services in a broad range of healthcare from biotechnology, genomics and diagnostics to healthcare services and medical devices. Current portfolio companies include AcelRx Pharmaceuticals, Intarcia Therapeutics, Keryx Biopharmaceuticals, Puma Biotechnology, Solta Medical and Tarsa Therapeutics.